| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
The primary target of 5-Hydroxymebendazole is β-tubulin, a key protein that forms microtubules. By binding to β-tubulin, the compound inhibits microtubule polymerization, which is essential for various cellular processes including mitosis, intracellular transport, and maintenance of cell shape. In helminths, this disruption of microtubule function impairs glucose uptake and depletes glycogen stores, leading to energy depletion and parasite death. The target is the same as that of the parent compound mebendazole.
|
|---|---|
| ln Vitro |
In vitro, 5-Hydroxymebendazole exhibits anthelmintic activity similar to that of mebendazole. It binds to β-tubulin and inhibits microtubule polymerization. The compound's activity is assessed using in vitro assays that measure its ability to inhibit the growth or survival of parasitic worms. It is also used as a reference standard in analytical assays to measure mebendazole and its metabolites in biological samples. However, detailed IC50 or EC50 values for 5-Hydroxymebendazole are not extensively reported in the available literature.
|
| ln Vivo |
In vivo, 5-Hydroxymebendazole is formed as a metabolite of mebendazole after oral administration. It contributes to the overall anthelmintic effect of the parent drug. The compound's in vivo activity is primarily studied in the context of mebendazole pharmacokinetics and pharmacodynamics. It is used as a marker of mebendazole metabolism and is measured in pharmacokinetic studies. However, 5-Hydroxymebendazole itself is not administered as a therapeutic agent.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for 5-Hydroxymebendazole typically involve measuring its binding affinity to β-tubulin. The compound is incubated with purified β-tubulin or with tubulin-rich preparations from parasitic worms. The binding affinity is measured using techniques such as surface plasmon resonance or fluorescence polarization. Alternatively, the compound's ability to inhibit tubulin polymerization can be assessed by monitoring the formation of microtubules in vitro using a spectrophotometric assay.
|
| Cell Assay |
Cellular assays for 5-Hydroxymebendazole are typically performed using parasitic worm cultures or mammalian cell lines. The compound's ability to inhibit the growth or survival of parasitic worms is assessed by incubating the worms with various concentrations of the compound and measuring viability. In mammalian cells, the compound's effects on microtubule dynamics can be assessed by immunofluorescence microscopy to visualize the microtubule cytoskeleton.
|
| Animal Protocol |
In vivo animal studies with 5-Hydroxymebendazole are not typically performed, as the compound is a metabolite rather than a primary therapeutic agent. However, animal studies with mebendazole would measure the formation of 5-Hydroxymebendazole as a pharmacokinetic endpoint. In such studies, animals are administered mebendazole, and blood and tissue samples are collected at various time points to measure the concentrations of mebendazole and its metabolites, including 5-Hydroxymebendazole. The pharmacokinetic parameters of the metabolite are then calculated.
|
| ADME/Pharmacokinetics |
As a metabolite of mebendazole, the pharmacokinetic properties of 5-Hydroxymebendazole are determined by the metabolism of the parent drug. Mebendazole is poorly absorbed orally and undergoes extensive first-pass metabolism, with 5-Hydroxymebendazole being a major metabolite. The compound has a molecular weight of 297.31. However, detailed pharmacokinetic parameters for the metabolite itself are not extensively reported. The compound is stable when stored as a powder at -20°C for up to 3 years.
|
| Toxicity/Toxicokinetics |
The toxicity of 5-Hydroxymebendazole is expected to be similar to that of its parent compound, mebendazole, as it is a major metabolite. Mebendazole is generally well-tolerated, with gastrointestinal side effects being the most common. However, specific toxicological data for 5-Hydroxymebendazole itself are not reported in the available literature. The compound is classified as a research-use-only chemical and is not intended for human consumption.
|
| Additional Infomation |
5-Hydroxybenzamide is a type of benzimidazole compound.
5-Hydroxymebendazole is a research-grade compound and the primary active metabolite of mebendazole. It is not approved for clinical use as a therapeutic agent. Its primary applications are in pharmacokinetic studies of mebendazole metabolism, as a reference standard for analytical method development, and as a tool for studying the mechanism of action of benzimidazole anthelmintics. The compound is also used in studies of drug metabolism and drug-drug interactions. |
| Molecular Formula |
C16H15N3O3
|
|---|---|
| Molecular Weight |
297.31
|
| Exact Mass |
297.111
|
| CAS # |
60254-95-7
|
| Related CAS # |
5-Hydroxymebendazole-d3;1173020-86-4
|
| PubChem CID |
43242
|
| Appearance |
White to off-white solid powder
|
| Density |
1.401g/cm3
|
| Boiling Point |
438.82°C (rough estimate)
|
| Index of Refraction |
1.716
|
| LogP |
2.836
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
22
|
| Complexity |
387
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC(NC1=NC2=C(N1)C=C(C(O)C3=CC=CC=C3)C=C2)=O
|
| InChi Key |
IIQKUGXEGMZCLE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H15N3O3/c1-22-16(21)19-15-17-12-8-7-11(9-13(12)18-15)14(20)10-5-3-2-4-6-10/h2-9,14,20H,1H3,(H2,17,18,19,21)
|
| Chemical Name |
methyl (5-(hydroxy(phenyl)methyl)-1H-benzo[d]imidazol-2-yl)carbamate
|
| Synonyms |
R-19167 R19167R 191675-Hydroxymebendazole
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3635 mL | 16.8175 mL | 33.6349 mL | |
| 5 mM | 0.6727 mL | 3.3635 mL | 6.7270 mL | |
| 10 mM | 0.3363 mL | 1.6817 mL | 3.3635 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
